A prospective, observational study of Xigris Use in the United States (XEUS)

Journal of Critical Care

Volumn 25, Issue 4, 2010, Pages 660.e9-660.e16

  Steingrub, Jay S ^a,b   Cheatham, Michael L ^c   Woodward, Brad ^d   Wang, H Tiffany ^d   Effron, Mark B ^d  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ORLANDO REGIONAL MEDICAL CENTER   (United States)

^d Lilly USA   (United States)

Author keywords

Drotrecogin alfa (activated); Protein C; Sepsis; Severe sepsis

Indexed keywords

DROTRECOGIN;

ACUTE DISEASE; ADULT; AGE DISTRIBUTION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INTENSIVE CARE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; SEPSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 78649445694     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2010.03.009     Document Type: Article

References (27)

1. Sands K.E., Bates D.W., Lanken P.N., et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997, 278:234-240.
2. Minino A.M., Heron M.P., Murphy S.L., et al. Deaths: final data for 2004. Natl Vital Stat Rep 2004, 55:1-119.
3. Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
4. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
5. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327.
6. The surviving sepsis campaign Available at:, Accessed March 28, 2008. http://www.survivingsepsis.org.
7. International sepsis forum Available at:, Accessed March 28, 2008. http://www.sepsisforum.org.
8. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
9. Ely E.W., Laterre P.F., Angus D.C., et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003, 31:12-19.
10. Wennberg D.E., Lucas F.L., Birkmeyer J.D., et al. Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. JAMA 1998, 279:1278-1281.
11. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995, 273:1421-1428.
12. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280:605-613.
13. Gladstone D.J., Black S.E. Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice. CMAJ 2001, 165:311-317.
14. Wieringa N.F., Vos R., Van der Werf G.T., et al. Co-morbidity of "clinical trial" versus "real-world" patients using cardiovascular drugs. Pharmacoepidemiol Drug Saf 2000, 9:569-579.
15. Safcsak K., Lipsett P., Effron M.D., et al. Safety of drotrecogin alfa (activated): results of XEUS, a prospective multicenter observational study [abstract]. CHEST 2004, 126:724S-a.
16. Rickert T., Steingrub J.S., Cheatham M.L., et al. Clinical use of drotrecogin alfa (activated): patients treated in the XEUS study differ from high-risk PROWESS patients [abstract]. CHEST 2004, 126:865S-a.
17. Steingrub J.S., Cheatham M.L., Safcsak K., et al. Improved outcomes in closed versus open medical ICUs among severe sepsis patients treated with drotrecogin alfa (activated) [abstract]. Crit Care Med 2004, 32:A145.
18. Linde-Zwirble W., Ernst F.R., Bates B. Resource use variation among severe sepsis patients treated with drotrecogin alfa (activated) in the XEUS study [abstract]. Crit Care Med 2004, 32:A69.
19. Safcsak K., Cheatham M.L., Steingrub J.S., et al. Surgical/trauma patients receiving drotrecogin alfa (activated) in clinical practice have outcomes similar to patients in PROWESS [abstract]. Crit Care Med 2004, 32:A145.
20. Knaus W.A., Draper E.A., Wagner D.P., et al. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
21. Wheeler A., Steingrub J., Schmidt G.A., et al. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial. Crit Care Med 2008, 36:14-23.
22. Ernst F.R., Viswanathan S., Vedarajan G. Challenges of identification of severe sepsis in administrative data and feasibility of an alternative method. Adv Sepsis 2005, 5:11-18.
23. Rosenthal G.E., Harper D.L., Quinn L.M., et al. Severity-adjusted mortality and length of stay in teaching and nonteaching hospitals. Results of a regional study. JAMA 1997, 278:485-490.
24. Kuhn E.M., Hartz A.J., Krakauer H., et al. The relationship of hospital ownership and teaching status to 30- and 180-day adjusted mortality rates. Med Care 1994, 32:1098-1108.
25. Payen D., Sablotzki A., Barie P.S., et al. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. Surgery 2006, 140:726-739.
26. Barie P.S., Hydo L.J., Shou J., et al. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. Surg Infect (Larchmt) 2006, 7:S77-S80. [abstract].
27. Barie P.S., Williams M.D., McCollam J.S., et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004, 188:212-220.